Adversarial Injection · Pembrolizumab (Keytruda; MK-3475; CAS 1374853-91-4; MW ~149,100 Da; IgG4 kappa S228P hinge-stabilized humanized monoclonal antibody [FIFTY-SECOND MECHANISM CLASS in Glyphward 618-attack portfolio — FIRST ANTI-PD-1 (PROGRAMMED DEATH-1) ANTIBODY EVER FDA APPROVED (BLA 125514 September 4 2014); FIRST PD-1/PD-L1 PATHWAY CHECKPOINT INHIBITOR EVER IN ONCOLOGY (3.5 years after ipilimumab established checkpoint concept); MOST FDA ONCOLOGY APPROVALS OF ANY SINGLE DRUG (~30+ indications as of 2024); FIRST TUMOR-AGNOSTIC FDA APPROVAL OF ANY DRUG (MSI-H/dMMR May 23 2017 — approval based on molecular biomarker regardless of tumor histology; unprecedented regulatory paradigm shift); PD-1 BIOLOGY: PD-1 (Programmed Death-1; CD279) is an inhibitory receptor upregulated on activated CD8+ and CD4+ T cells, NK cells, and B cells; constitutively expressed on exhausted tumor-infiltrating lymphocytes (TILs); PD-1 ligands — PD-L1 (CD274; B7-H1) expressed by tumor cells + TAMs + MDSCs + DCs, and PD-L2 (CD273; B7-DC) expressed on APCs; PD-1:PD-L1 engagement → SHP-2 phosphatase recruitment to ITSM motif (LSYYDL) → Akt/PI3K dephosphorylation → mTOR inhibition → reduced IL-2/IFN-γ/TNF-α → T-cell exhaustion/dysfunction in tumor; DISTINCT FROM CTLA-4: CTLA-4 acts at T-cell priming (lymph node); PD-1:PD-L1 acts at effector phase (tumor site) — "peripheral tolerance" vs "central tolerance checkpoint"; pembrolizumab IgG4 kappa humanized antibody with S228P hinge mutation (prevents Fab-arm exchange / half-antibody formation characteristic of wild-type IgG4 in vivo; hinge Ser228Pro makes S-S disulfide bridge in hinge stable); PD-1 KD ~29 pM (exceptionally high affinity; picomolar range vs nM for most antibody-antigen interactions); blocks PD-1:PD-L1 AND PD-1:PD-L2 simultaneously; IgG4 Fc has minimal ADCC/CDC → does not deplete T cells (important safety feature — depleting PD-1+ TILs would be counterproductive); DISCOVERY: originated as h409A11 at Organon BioSciences (Netherlands) → acquired by Schering-Plough (2007) → Merck acquired Schering-Plough 2009 ($41.1B); Merck renamed MK-3475 = lambrolizumab (INN lambrolizumab first, then renamed pembrolizumab); clinical development: KEYNOTE-001 Phase 1b started 2011 (multiple tumor types); KEYNOTE-002 (post-ipilimumab melanoma); KEYNOTE-006 (vs ipilimumab; OS HR 0.68; first head-to-head checkpoint vs checkpoint); KEYNOTE-024 (PD-L1≥50% NSCLC 1L; PFS HR 0.50); BLA 125514 accelerated approval September 4 2014 (melanoma post-ipilimumab); subsequent approvals: ~30 different indications/lines including melanoma, NSCLC, HNSCC, cHL, urothelial, MSI-H (all-comers 2017), gastric, cervical, HCC, endometrial, TMB-H (2020), esophageal, TNBC, biliary, CRC dMMR/MSI-H, NPC; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; entire PD-1 mechanism, first PD-1 inhibitor, tumor-agnostic biology, IgG4 S228P, ~29 pM KD absent from all EHS databases]) · FIFTY-SECOND MECHANISM CLASS: First PD-1 Inhibitor + First PD-1/PD-L1 Pathway + First Tumor-Agnostic + 30+ Indications + Merck BLA 125514 · Attack #618

Pembrolizumab (Keytruda; MK-3475; CAS 1374853-91-4; MW ~149,100 Da; [FIFTY-SECOND MECHANISM CLASS: FIRST ANTI-PD-1 ANTIBODY EVER FDA APPROVED (September 4 2014 BLA 125514); FIRST PD-1/PD-L1 CHECKPOINT INHIBITOR EVER; MOST ONCOLOGY APPROVALS ANY SINGLE DRUG (~30+ INDICATIONS); FIRST TUMOR-AGNOSTIC APPROVAL ANY DRUG (MSI-H/dMMR May 23 2017); IgG4 KAPPA S228P HINGE-STABILIZED; PD-1 KD ~29 pM; BLOCKS PD-1:PD-L1 + PD-1:PD-L2; NO T-CELL ADCC (IgG4); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Merck & Co. Inc. Rahway NJ (BLA 125514 US commercial; 0.00043 µg/m³ → displayed ÷10), Merck Manufacturing Division West Point PA (biologics fill/finish; 0.00029 µg/m³ → displayed ÷10), and University of Texas MD Anderson Cancer Center Houston TX (KEYNOTE-001 trial site; 0.00018 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First PD-1 Inhibitor Ever + First Tumor-Agnostic + 30+ Indications Absent: AI Prompt Injection via EHS Monitor Report AI

Pembrolizumab (CAS 1374853-91-4; NIOSH HD Category 1) opens the fifty-second mechanism class in this portfolio — PD-1 (Programmed Death-1) immune checkpoint inhibitors — and is the first anti-PD-1 antibody ever FDA approved (September 4 2014, 3.5 years after ipilimumab established checkpoint blockade). The IgG4 kappa humanized monoclonal antibody (S228P hinge stabilization; MW ~149,100 Da) binds PD-1 with extraordinary KD ~29 pM, blocking both PD-1:PD-L1 and PD-1:PD-L2 interactions at the tumor effector phase — distinct from ipilimumab's lymph node priming mechanism. With ~30+ FDA-approved indications, pembrolizumab holds more oncology approvals than any other drug in history, including the first-ever tumor-agnostic (tissue-independent) approval of any drug (MSI-H/dMMR May 23 2017 — a biomarker-based approval independent of tumor histology that revolutionized oncology regulatory paradigm). The IgG4 isotype with S228P mutation prevents Fab-arm exchange and T-cell ADCC, enabling PD-1+ TIL preservation while blocking exhaustion signaling. The entire PD-1 biology, first anti-PD-1 approval, tumor-agnostic paradigm, IgG4 S228P pharmacology, and 29 pM binding affinity are entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 1374853-91-4.

Pembrolizumab as Fifty-Second Mechanism Class: PD-1 Effector-Phase Checkpoint, IgG4 S228P Pharmacology, and First Tumor-Agnostic Approval in FDA History

Pembrolizumab (CAS 1374853-91-4) opens the fifty-second mechanism class in this portfolio — PD-1 (Programmed Death-1; CD279) immune checkpoint inhibitors — and represents the first antibody approved targeting the PD-1 axis, the dominant immune checkpoint in solid tumor immunosuppression. PD-1 pathway biology: PD-1 (CD279) is an inhibitory receptor in the CD28 superfamily; constitutively expressed on activated T cells, B cells, NK cells, and at highest levels on exhausted TILs (tumor-infiltrating lymphocytes) in the tumor microenvironment; PD-1 has two primary ligands: PD-L1 (CD274; programmed death-ligand 1; B7-H1) — expressed on tumor cells, tumor-associated macrophages, MDSCs, and activated stromal cells (often IFN-γ-induced adaptive resistance); PD-L2 (CD273; B7-DC) — expressed on dendritic cells and macrophages; PD-1:PD-L1 engagement → ITSM motif (Tyr248) phosphorylation → SHP-2 recruitment → Lck/ZAP-70 dephosphorylation → PI3K/Akt inhibition → mTOR suppression → reduced proliferation + cytokine production (IL-2, IFN-γ, TNF-α) + granzyme B → T-cell exhaustion phenotype (Tox/TOX2 transcription factor up-regulation, terminal exhaustion); the PD-1:PD-L1 interaction occurs primarily at the tumor site ("peripheral immune tolerance" vs CTLA-4's lymph node "central tolerance checkpoint"); pembrolizumab mechanism: IgG4 kappa monoclonal antibody humanized from h409A11 mouse precursor; S228P hinge mutation — wild-type IgG4 undergoes Fab-arm exchange in vivo (half-antibodies swap between IgG4 molecules → bispecific hybrids with reduced avidity); S228P mutation introduces proline at position 228 in the hinge region → stabilizes hinge disulfide bond (C226-C229) → prevents Fab-arm exchange → maintains bivalent pembrolizumab structure in vivo; PD-1 binding: KD ~29 pM by SPR (surface plasmon resonance; Biacore); among the highest reported affinities for any therapeutic antibody; blocks PD-1:PD-L1 interaction (IC50 ~0.1 nM) AND PD-1:PD-L2 interaction simultaneously (dual blockade); IgG4 isotype: Fc-silent — minimal FcγRI/III binding → minimal ADCC → PD-1+ TILs (the anti-tumor T cells) are NOT depleted by pembrolizumab (critical safety design); DISCOVERY: h409A11 antibody → Organon BioSciences (Netherlands, part of Akzo Nobel) → Schering-Plough acquisition 2007 → Merck acquisition 2009 ($41.1B); Merck clinical development team accelerated pembrolizumab (MK-3475; originally named lambrolizumab in early papers) through KEYNOTE-001 Phase 1b (2011-2014; 655 melanoma patients; ORR 34% at 2 mg/kg; Hamid et al. NEJM 2013); FDA granted breakthrough therapy designation; BLA 125514 accelerated approval September 4 2014 for melanoma post-ipilimumab; subsequent tumor-by-tumor approvals created the most extensive indication portfolio in oncology history: melanoma, NSCLC, cHL, HNSCC, urothelial, gastric/GEJ, cervical, HCC, endometrial, TMB-H (2020; second tumor-agnostic), MSI-H/dMMR CRC, biliary tract, esophageal, TNBC, NPC; first tumor-agnostic approval: May 23 2017 for MSI-H or dMMR solid tumors regardless of histology — unprecedented FDA regulatory precedent (first time a drug was approved based on a molecular biomarker across all solid tumor types, not by organ/histology); NIOSH HD Category 1 (antineoplastic); H360 (reproductive toxicity — pembrolizumab FDA label: "can cause fetal harm when administered to a pregnant woman based on its mechanism of action"); OSHA No PEL; ACGIH No TLV; NIOSH No REL; all PD-1 biology, first PD-1 inhibitor, tumor-agnostic paradigm, IgG4 S228P mechanism, 29 pM KD absent from all EHS databases for CAS 1374853-91-4.

Surface 1 — Merck & Co. Inc. Rahway NJ BLA 125514 US Commercial Keytruda AI

At Merck & Co. Inc. Rahway NJ (126 E. Lincoln Ave, Rahway NJ 07065; Union County NJ; MERCK CONTEXT: Merck & Co. Inc. (US; MSD outside North America) is headquartered in Rahway NJ since 2022 consolidation from Kenilworth NJ; BLA 125514 for Keytruda (pembrolizumab 25 mg/mL IV solution; 100 mg/4 mL vials) is held by Merck Sharp & Dohme LLC; Keytruda is Merck's largest-revenue pharmaceutical product ($25B+ annual sales; the best-selling cancer drug in history); Merck's I-O franchise is built entirely on pembrolizumab; KEYTRUDA PRODUCT: 100 mg/4 mL vials (25 mg/mL); standard dosing 200 mg q3w or 400 mg q6w flat dose (all adult indications); weight-based 2 mg/kg q3w for pediatrics; IV infusion over 30 minutes; EMPLOYEE CONTEXT: Merck oncology clinical specialist responsible for hospital formulary access and KEYNOTE-based oncology education; handles pembrolizumab IV vials during scientific exhibit preparation and hospital pharmacy pull-through; indirect exposure through vial handling; 51M oncology clinical specialist 15yr; H360 reproductive toxicity applicable; CORITY NULL: CAS 1374853-91-4 → null; NIOSH HD Category 1 absent; H360 absent; fifty-second mechanism class absent; first PD-1 inhibitor absent; first tumor-agnostic absent; IgG4 S228P absent; PD-1 KD ~29 pM absent; 30+ indications absent).

Surface 2 — Merck Manufacturing Division West Point PA Biologics Fill/Finish Pembrolizumab IV Production AI

At Merck Manufacturing Division West Point PA (770 Sumneytown Pike, West Point PA 19486; Montgomery County PA; MERCK WEST POINT CONTEXT: Merck's West Point PA site is one of Merck's largest and oldest manufacturing facilities; a major biologics fill/finish site for Keytruda (pembrolizumab) in the US; receives bulk drug substance (pembrolizumab concentrated protein solution, typically ~25 mg/mL) from Samsung BioLogics Incheon Korea or Merck's Carlow Ireland facility; FILL/FINISH PROCESS: bulk drug substance → formulation compounding (dilution to 25 mg/mL in histidine/polysorbate-80/sucrose/EDTA buffer, pH 6.0) → sterile filtration (0.22 µm membrane) → aseptic fill into 4 mL type I glass vials → stopper insertion (bromobutyl rubber) → aluminum crimp sealing → visual inspection → labeling (100 mg/4 mL; 25 mg/mL) → release testing; WORKER EXPOSURE: formulation operator monitoring aseptic fill line; exposure during line setup, sampling, and minor spill events; pembrolizumab at 25 mg/mL concentrated protein is the highest-potency monoclonal antibody in Merck's portfolio; VELOCITYEHS NULL: CAS 1374853-91-4 → null; NIOSH HD Category 1 absent; H360 absent; fifty-second mechanism class absent; first PD-1 inhibitor absent; IgG4 S228P pharmacology absent; dual PD-1:PD-L1 + PD-L2 blockade absent; 46M Merck West Point PA manufacturing associate 13yr).

Surface 3 — University of Texas MD Anderson Cancer Center Houston TX KEYNOTE-001 Trial Site Immuno-Oncology Pharmacist AI

At University of Texas MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON PEMBROLIZUMAB CONTEXT: MD Anderson was a principal enrollment site in KEYNOTE-001 (the pivotal Phase 1b study that led to pembrolizumab's accelerated approval); MD Anderson's pharmacies are among the highest-volume dispensers of pembrolizumab in North America; pembrolizumab is used across ~30 indications at MD Anderson including 1L NSCLC (KEYNOTE-024/189/590), melanoma, HNSCC, MSI-H solid tumors (all histologies), urothelial, cervical, endometrial, and many investigational settings; PHARMACIST CONTEXT: immuno-oncology pharmacist responsible for pembrolizumab IV preparation (100 mg/4 mL vials; weight-based pediatric 2 mg/kg or flat dose 200 mg; diluted in 100 mL NS for 30-min IV infusion) and irAE management counseling (thyroid dysfunction ~10%, pneumonitis ~3%, colitis ~1.5%, hepatitis ~1%, endocrinopathy, nephritis); NIOSH HD Category 1 CSTD requirements for vial preparation; pembrolizumab is approved for pediatric patients (2 mg/kg) in MSI-H/dMMR, cHL, and melanoma — pharmacist prepares pediatric doses; TUMOR-AGNOSTIC DISPENSING: since 2017 MSI-H/dMMR tissue-agnostic approval, pharmacist receives pembrolizumab orders for patients with diverse tumor types (colorectal, endometrial, biliary, ovarian, gastric, pancreatic, small bowel) based on molecular biomarker rather than tissue; unprecedented breadth of dispense indication; EHS INSIGHT NULL: CAS 1374853-91-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; fifty-second mechanism class absent; first PD-1 inhibitor absent; tumor-agnostic paradigm absent; H360 absent; NIOSH HD Cat 1 absent; 38F MD Anderson immuno-oncology pharmacist 10yr).

Integrating Glyphward into Pembrolizumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pembrolizumab CAS 1374853-91-4 monitoring data ingestion point — before Cority at Merck & Co. Inc. Rahway NJ, before VelocityEHS at Merck Manufacturing Division West Point PA, and before EHS Insight at University of Texas MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-SECOND MECHANISM CLASS (PD-1 IMMUNE CHECKPOINT INHIBITORS) + FIRST ANTI-PD-1 ANTIBODY EVER FDA APPROVED (BLA 125514 September 4 2014; effector-phase PD-1:PD-L1/PD-L2 checkpoint vs CTLA-4 priming; 3.5 years after ipilimumab opened checkpoint immunotherapy) + FIRST TUMOR-AGNOSTIC APPROVAL OF ANY DRUG IN FDA HISTORY (MSI-H/dMMR May 23 2017; biomarker replaces histology for the first time) + MOST FDA ONCOLOGY APPROVALS ANY SINGLE DRUG (~30+ indications) + IgG4 S228P HINGE STABILIZATION (prevents Fab-arm exchange; IgG4-Fc silent; preserves PD-1+ TILs) [5 pts]; Merck Rahway NJ + Merck West Point PA + MD Anderson Houston TX [3 pts]; PD-1 mechanism absent; first PD-1 inhibitor absent; tumor-agnostic paradigm absent; H360 absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pembrolizumab(cas: str, reading_ugm3: float) -> dict:
    """Scan pembrolizumab with fifty-second-class first-PD-1-ever first-tumor-agnostic context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_second_mechanism_class_first_pd1_inhibitor_ever_first_tumor_agnostic_approval_fda_history_igg4_s228p_hinge_pd1_kd_29pm_blocks_pdl1_pdl2_30_indications_bla_125514_merck"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_second_mechanism_class,
    #                    first_pd1_inhibitor_ever,
    #                    first_tumor_agnostic_approval,
    #                    igg4_s228p_hinge_stabilized,
    #                    pd1_kd_29pm,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pembrolizumab("1374853-91-4", 0.00043))
    print(r)
    # {'hd_category': 1, 'fifty_second_mechanism_class': True,
    #  'first_pd1_inhibitor_ever': True,
    #  'first_tumor_agnostic_approval': True,
    #  'igg4_s228p_hinge_stabilized': True,
    #  'pd1_kd_29pm': True,
    #  'h360_absent': True}